Strategies for Effective Discontinuation of Proton Pump Inhibitors

被引:14
作者
Kim J. [1 ]
Blackett J.W. [1 ]
Jodorkovsky D. [1 ]
机构
[1] Division of Digestive and Liver Diseases, Columbia University Medical Center, 161 Fort Washington Ave Suite 862, New York, 10032, NY
关键词
Hypergastrinemia; On-demand therapy; Proton pump inhibitors; Reflux hypersensitivity; Step-down therapy;
D O I
10.1007/s11894-018-0632-y
中图分类号
学科分类号
摘要
Purpose of Review: Proton pump inhibitors (PPIs) are effective for many conditions but are often overprescribed. Recent concerns about long-term risks have made patients re-evaluate their need to take PPIs chronically, though these population-based studies have methodological weaknesses. The goal of this review is to provide evidenced-based strategies for discontinuation of PPI therapy. Recent Findings: Given that some patients experience rebound symptoms when abruptly stopping continuous PPI therapy due to its effect on hypergastrinemia, strategies focus on avoiding rebound. Tapering the PPI and then initiating a “step-down” approach with the use of alternative medications may be effective. “On-demand therapy” provides patients with the option to take intermittent PPI courses, reducing overall use and cost while preserving patient satisfaction. It is important for providers to consider ambulatory pH or pH/impedance testing to rule out diagnoses that may require alternative medications like neuromodulators. Summary: A number of studies reviewed here can provide guidance in counseling patients on PPI discontinuation. It is important for the provider to obtain a baseline needs assessment for PPI therapy and to elucidate predictors of difficulty in discontinuation prior to initiating a strategy. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 32 条
[1]  
Forgacs I., Loganayagam A., Overprescribing proton pump inhibitors, BMJ, 336, pp. 2-3, (2008)
[2]  
Gawron A.J., Feinglass J., Pandolfino J.E., Tan B.K., Bove M.J., Shintani-Smith S., Brand name and generic proton pump inhibitor prescriptions in the United States: insights from the national ambulatory medical care survey (2006-2010), Gastroenterol Res Pract, 2015, (2015)
[3]  
Katz M.H., Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users, Arch Intern Med, 170, pp. 747-748, (2010)
[4]  
Moayyedi P., Delaney B.C., Vakil N., Forman D., Talley N.J., The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis, Gastroenterology, 127, pp. 1329-1337, (2004)
[5]  
Wolfe M.M., Sachs G., Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome, Gastroenterology, 118, pp. S9-S31, (2000)
[6]  
DeVault K.R., Castell D.O., American College of G., Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease, Am J Gastroenterol, 100, pp. 190-200, (2005)
[7]  
Freedberg D.E., Kim L.S., Yang Y.X., The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association, Gastroenterology, 152, pp. 706-715, (2017)
[8]  
Heidelbaugh J.J., Goldberg K.L., Inadomi J.M., Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting, Am J Manag Care, 16, pp. e228-e234, (2010)
[9]  
Eid S.M., Boueiz A., Paranji S., Mativo C., Landis R., Abougergi M.S., Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists, Intern Med, 49, pp. 2561-2568, (2010)
[10]  
Lanas A., We are using too many PPIs, and we need to stop: a European perspective, Am J Gastroenterol, 111, pp. 1085-1086, (2016)